Overexpression of microRNA-345 Affects the Invasive Capacity of Pancreatic Ductal Adenocarcinoma Cell Lines by Suppressing MUC1 and TJP2 Expression
Source abstract
Abstract
The majority of pancreatic carcinomas are pancreatic ductal adenocarcinomas (PDAC), and the presence of non-invasive pancreatic intraepithelial neoplasia or intraductal papillary mucinous neoplasm, as an associated lesion, is considered important. These microscopic hyperplastic or grossly papillomatous lesions exhibit varying degrees of morphological atypia and may develop into invasive carcinomas. In this study, we investigated whether mucin-1 (MUC1) is involved in the progression of pancreatic carcinoma and examined the mechanisms by which microRNAs regulate MUC1 expression in vitro. In PDAC cell lines, suppression of MUC1 expression reduced cell proliferation and invasion; PDAC cell lines transfected with an miR-345 precursor suppressed the expression of MUC1, and reduced cell proliferation and invasion. Tight junction protein 2 (TJP2), a putative target of miR-345, is regulated by MUC1. The suppression of TJP2 expression reduced cell proliferation by inducing apoptosis. These results suggest that MUC1 and TJP2, the putative target molecules of miR-345, are critical in maintaining the invasive potential of pancreatic carcinoma cells, and regulating their expression may prevent the progression of non-invasive pancreatic intraductal lesions to invasive carcinomas. This study provides new insights for the development of novel molecular targeted therapies for pancreatic carcinomas.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Pancreatic and Hepatic Oncology Research · Caveolin-1 and cellular processes · Galectins and Cancer Biology
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Diagnostic Pathology, Nara Medical University School of Medicine, Nara 634-8521, Japan
Department of Central Clinical Laboratory, Nara Medical University Hospital, Nara 634-8521, Japan
Department of Surgery, Nara Medical University School of Medicine, Nara 634-8521, Japan
Funding
Japanese Ministry of Education, Culture, Sports, Science, and Technology
References (46)
Show source-provided references
1. Progression model for pancreatic cancer
2. An Illustrated Consensus on the Classification of Pancreatic Intraepithelial Neoplasia and Intraductal Papillary Mucinous Neoplasms10.1097/01.pas.0000126675.59108.80 ↗
3. The Dichotomy in the Preinvasive Neoplasia to Invasive Carcinoma Sequence in the Pancreas: Differential Expression of MUC1 and MUC2 Supports the Existence of Two Separate Pathways of Carcinogenesis10.1097/01.MP.0000028647.98725.8B ↗
4. Increased expression of MUC1 in advanced pancreatic cancer10.1007/s00535-003-1224-6 ↗
5. Tumorigenesis and phenotypic characteristics of mucin-producing bile duct tumors: An immunohistochemical approach10.1007/s00534-009-0158-7 ↗
6. Significance of mucin expression in pancreatobiliary neo-plasms10.1007/s00534-009-0174-7 ↗
7. MUC-1 mucin expression in invasive areas of intraductal papillary mucinous tumors of the pancreas10.1111/j.1440-1827.1998.tb03913.x ↗
8. MicroRNA expression and function in cancer10.1016/j.molmed.2006.10.006 ↗
9. MicroRNA and cancer10.1016/j.molonc.2012.09.006 ↗
10. Differential MUC 1 expression in normal and neoplastic human pancreatic tissue. An immunohistochemical study of 60 samples10.1093/ajcp/112.5.635 ↗
11. Mucin 1 Regulates Cox-2 Gene in Pancreatic Cancer10.1097/MPA.0000000000000371 ↗
12. A novel association of neuropilin-1 and MUC1 in pancreatic ductal adenocarcinoma: Role in induction of VEGF signaling and angiogenesis10.1038/onc.2015.516 ↗
13. Inhibition of MUC1-C Increases ROS and Cell Death in Mouse Embryonic Stem Cells
14. Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and in-ducing ROS-mediated myeloma cell death10.1182/blood-2013-11-539395 ↗
15. Human MUC1 Carcinoma Antigen Regulates Intracellular Oxidant Levels and the Apoptotic Response to Oxidative Stress10.1074/jbc.M301987200 ↗
16. MUC1 and MUC2 expression in pancreatic ductal carcinoma obtained by fine-needle aspiration10.1002/cncr.11857 ↗
17. Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: Application of CDX2, CK17, MUC1, and MUC210.1097/01.pas.0000149708.12335.6a ↗
18. Biphasic Alterations in Expression and Subcellular Localization of MUC1 in Pancreatic Ductal Carcinogenesis in Syrian Hamsters10.1097/MPA.0000000000000178 ↗
19. MUC1 Promoter–Driven DTA as a Targeted Therapeutic Strategy against Pancreatic Cancer10.1158/1541-7786.MCR-14-0199 ↗
20. Aberrant methylation of MUC1 and MUC4 promoters are potential prognostic biomarkers for pancreatic ductal adenocarcinomas10.18632/oncotarget.9924 ↗
21. MicroRNA Expression Patterns to Differentiate Pancreatic Adenocarcinoma from Normal Pancreas and Chronic Pancreatitis10.1001/jama.297.17.1901 ↗
22. Cell-Free Plasma MicroRNA in Pancreatic Ductal Adenocarcinoma and Disease Controls10.1097/MPA.0b013e318296bb34 ↗
23. MicroRNA-454 regulates stromal cell derived factor-1 in the control of the growth of pancreatic ductal adenocarcinoma10.1038/srep22793 ↗
24. Felix, T.F., Lapa, R.M.L., De Carvalho, M., Bertoni, N., Tokar, T., Oliveira, R.A., Rodrigues, M.A.M., Hasimoto, C.N., Oliveira, W.K., and Pelafsky, L. (2019). MicroRNA modulated networks of adaptive and innate immune response in pancreatic ductal adenocarcinoma. PLoS ONE, 14.10.1371/journal.pone.0217421 ↗
25. Analyzing miRNAs in ductal adenocarcinomas of the pancreas10.1016/j.jss.2009.10.005 ↗
26. A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases10.1053/j.gastro.2020.04.057 ↗
27. Diagnostic and biological significance of microRNA-192 in pancreatic ductal adenocarcinoma10.3892/or.2013.2420 ↗
28. TGF-beta induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression10.1038/s41467-018-03962-x ↗
29. Mir34a constrains pancreatic carcinogenesis10.1038/s41598-020-66561-1 ↗
30. Shen, Y., Pu, K., Zheng, K., Ma, X., Qin, J., Jiang, L., and Li, J. (2019). Differentially Expressed microRNAs in MIA PaCa-2 and PANC-1 Pancreas Ductal Adenocarcinoma Cell Lines are Involved in Cancer Stem Cell Regulation. Int. J. Mol. Sci., 20.10.3390/ijms20184473 ↗
31. Prognostic significance of microRNA-141 expression and its tumor suppressor function in human pancreatic ductal adenocarcinoma10.1007/s11010-013-1897-y ↗
32. HEG1-responsive microRNA-23b regulates cell proliferation in malignant mesothelioma cells10.1016/j.bbrc.2020.03.172 ↗
33. Fujii, T., Shimada, K., Asano, A., Tatsumi, Y., Yamaguchi, N., Yamazaki, M., and Konishi, N. (2016). MicroRNA-331-3p Suppresses Cervical Cancer Cell Proliferation and E6/E7 Expression by Targeting NRP2. Int. J. Mol. Sci., 17.10.3390/ijms17081351 ↗
34. Syndecan-1 responsive microRNA-126 and 149 regulate cell proliferation in prostate cancer10.1016/j.bbrc.2014.11.056 ↗
35. Fujii, T., Shimada, K., Tatsumi, Y., Hatakeyama, K., Obayashi, C., Fujimoto, K., and Konishi, N. (2015). microRNA-145 promotes differentiation in human urothelial carcinoma through down-regulation of syndecan-1. BMC Cancer, 15.10.1186/s12885-015-1846-0 ↗
36. Syndecan-1 up-regulates microRNA-331-3p and mediates epithelial-to-mesenchymal transition in prostate cancer10.1002/mc.22381 ↗
37. Evaluation of DNA and RNA quality from archival formalin-fixed paraffin-embedded tissue for next-generation sequencing—Retrospective study in Japanese single institution10.1111/pin.12969 ↗
38. MicroRNA-345 functions as a tumor suppressor via targeting ZEB2 in oral squamous cell carcinoma10.1016/j.archoralbio.2020.104732 ↗
39. miR-345 inhibits tumor metastasis and EMT by targeting IRF1-mediated mTOR/STAT3/AKT pathway in hepatocellular carcinoma10.3892/ijo.2017.3852 ↗
40. MicroRNA-345 inhibits hepatocellular carcinoma metastasis by inhibiting YAP110.3892/or.2017.5772 ↗
41. MicroRNA-345 suppresses cell invasion and migration in non-small cell lung cancer by directly targeting YAP1
42. Paediatric hepatocellular carcinoma in tight junction protein 2 (TJP2) deficiency10.1007/s00428-017-2204-1 ↗
43. TJP2 hepatobiliary disorders: Novel variants and clinical diversity10.1002/humu.23947 ↗
44. A next generation connectivity map: L1000 platform and the first 1,000,000 profiles10.1016/j.cell.2017.10.049 ↗
45. Gene signatures and potential therapeutic targets of amino acid metabolism in estrogen recep-tor-positive breast cancer
46. Yuan, M., Shong, K., Li, X., Ashraf, S., Shi, M., Kim, W., Nielsen, J., Turkez, H., Shoaie, S., and Uhlen, M. (2022). A Gene Co-Expression Network-Based Drug Repositioning Approach Identifies Candidates for Treatment of Hepatocellular Carcinoma. Cancers, 14.10.3390/cancers14061573 ↗